NO992260D0 - Recombinant bicistronadenovirus for the treatment of pathological conditions associated with dyslipoproteinemia - Google Patents

Recombinant bicistronadenovirus for the treatment of pathological conditions associated with dyslipoproteinemia

Info

Publication number
NO992260D0
NO992260D0 NO992260A NO992260A NO992260D0 NO 992260 D0 NO992260 D0 NO 992260D0 NO 992260 A NO992260 A NO 992260A NO 992260 A NO992260 A NO 992260A NO 992260 D0 NO992260 D0 NO 992260D0
Authority
NO
Norway
Prior art keywords
bicistronadenovirus
dyslipoproteinemia
recombinant
treatment
conditions associated
Prior art date
Application number
NO992260A
Other languages
Norwegian (no)
Other versions
NO992260L (en
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO992260L publication Critical patent/NO992260L/en
Publication of NO992260D0 publication Critical patent/NO992260D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
NO992260A 1996-11-15 1999-05-10 Recombinant bicistronadenovirus for the treatment of pathological conditions associated with dyslipoproteinemia NO992260D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (en) 1996-11-15 1996-11-15 BICISTRONIC RECOMBINANT VIRUSES USEFUL FOR THE TREATMENT OF DYSLIPOPROTEINEMIA-RELATED CONDITIONS
PCT/FR1997/002043 WO1998022606A1 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Publications (2)

Publication Number Publication Date
NO992260L NO992260L (en) 1999-05-10
NO992260D0 true NO992260D0 (en) 1999-05-10

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992260A NO992260D0 (en) 1996-11-15 1999-05-10 Recombinant bicistronadenovirus for the treatment of pathological conditions associated with dyslipoproteinemia

Country Status (14)

Country Link
EP (1) EP0941355A1 (en)
JP (1) JP2001506488A (en)
KR (1) KR20000053320A (en)
AU (1) AU721654B2 (en)
BR (1) BR9712957A (en)
CA (1) CA2271437A1 (en)
CZ (1) CZ170399A3 (en)
FR (1) FR2755975B1 (en)
HU (1) HUP9904500A3 (en)
IL (1) IL129823A0 (en)
NO (1) NO992260D0 (en)
SK (1) SK63499A3 (en)
WO (1) WO1998022606A1 (en)
ZA (1) ZA9710271B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064392A2 (en) * 1998-03-16 2001-01-03 Introgen Therapeutics, Inc. Multigene vectors
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
AU2001247648B2 (en) * 2000-03-24 2006-03-30 Cold Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
EP1392504A4 (en) 2001-04-02 2008-03-05 Agilent Technologies Inc Sensor surfaces for detecting analytes
EP2741766B1 (en) * 2011-08-08 2015-10-07 Aptalis Pharma Limited Method for dissolution testing of solid compositions containing digestive enzymes
JP7316711B2 (en) * 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド A replicating oncolytic adenovirus that regulates lipid metabolism and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213779T1 (en) * 1991-08-07 2002-03-15 W French Anderson INTERNAL RIBOSOME ENTRY SITES CONTAIN RETROVIRAL VECTORS
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
FR2722208B1 (en) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
EP0787200B1 (en) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES EXPRESSING LECITHIN CHOLESTEROL ACYLTRANSFERASE AND USES IN GENE THERAPY

Also Published As

Publication number Publication date
FR2755975A1 (en) 1998-05-22
HUP9904500A2 (en) 2000-05-28
WO1998022606A1 (en) 1998-05-28
SK63499A3 (en) 2000-05-16
CZ170399A3 (en) 1999-08-11
KR20000053320A (en) 2000-08-25
AU5125298A (en) 1998-06-10
HUP9904500A3 (en) 2002-01-28
JP2001506488A (en) 2001-05-22
CA2271437A1 (en) 1998-05-28
EP0941355A1 (en) 1999-09-15
NO992260L (en) 1999-05-10
BR9712957A (en) 2000-02-01
IL129823A0 (en) 2000-02-29
FR2755975B1 (en) 1999-05-07
AU721654B2 (en) 2000-07-13
ZA9710271B (en) 1998-08-21

Similar Documents

Publication Publication Date Title
PT936908E (en) UTERIC ANTICONVULSIVE DERIVATIVES IN THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS (ELA)
NO20005864D0 (en) Quinasols for the treatment of brain tumor
FI971568A (en) Procedure for the treatment of resistant tumors
NO20005884L (en) Combination therapy for the treatment of bipolar disorders
DK0752870T3 (en) Use of Mycobacterium for the treatment of tumors
NO991459D0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
NO992260D0 (en) Recombinant bicistronadenovirus for the treatment of pathological conditions associated with dyslipoproteinemia
FI962420A0 (en) Foerstaerkare med laogbrus
NO991734D0 (en) Pyrazolinones for the treatment of potency disorders
NO984189D0 (en) Procedure for the treatment of bipolar disorder
NO20003481D0 (en) Procedure for the treatment of COPD
NO991158L (en) Procedure for the treatment of amyotrophic lateral sclerosis
NO920983D0 (en) PROCEDURE FOR THE TREATMENT OF NEVRODEGENERATIVE CONDITIONS
DE69616508T2 (en) Cocoa treatment
DE9414208U1 (en) Lower part of the fitting
NO20002481D0 (en) Combination therapy for the treatment of AIDS
NO952411D0 (en) Means for the treatment of metabolic bone disorders
IT1281294B1 (en) JEWEL AND PROCEDURE FOR THE REALIZATION OF THE SAME.
IT1277048B1 (en) PROCEDURE FOR THE PREPARATION OF CEPHALOSPORINS THROUGH DICARBONIL REDUCIVE CYCLING FOR TREATMENT WITH
NO962812D0 (en) Procedure for the treatment of pneumonia
KR960022630U (en) Furnace of the furnace
NO984190D0 (en) Procedure for the treatment of insomnia
NO996166L (en) Procedures for the treatment of odluor
KR960003453U (en) Vertical angle adjuster of the television